← DaVita HealthCare Partners overview

DaVita HealthCare Partners vs NeoGenomics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

DaVita HealthCare Partners Inc (DVA)

Q3 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

July 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

Latest
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

NeoGenomics Inc (NEO)

Q3 2026
▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

  • FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.

    New product launch is a fresh growth driver that directly boosts revenue potential.

  • Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.

    Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.

  • Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.

    Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.

  • CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.

    Leadership change is a new event that can affect investor confidence and future strategy.

August 2026
▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

  • FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.

    New product launch is a fresh growth driver that directly boosts revenue potential.

  • Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.

    Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.

  • Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.

    Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.

  • CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.

    Leadership change is a new event that can affect investor confidence and future strategy.

Latest
▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

  • FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.

    New product launch is a fresh growth driver that directly boosts revenue potential.

  • Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.

    Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.

  • Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.

    Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.

  • CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.

    Leadership change is a new event that can affect investor confidence and future strategy.